The nation of Zimbabwe has turned down a significant US health deal valued at $367m (272 million pounds) spanning five years due to the United States' insistence on sensitive biological samples.
The decision was revealed after a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government representative has since clarified that the US was requesting biological samples for research and commercial purposes while refused to guarantee the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further dialogue to reach a agreement acceptable to all parties so the country's vital HIV programme can be sustained.
Broader Implications
This development follows a similar case in neighbouring Kenya, where a court blocked a similar deal with the US following legal challenges were raised about the security of Kenyans' medical information.
After resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government deals to boost openness and accountability.
According to reports, 16 nations in Africa have so far agreed to similar agreements, representing more than $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to surrender its biological resources and data over an extended period, without any corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"In essence, our country would provide the basic resources for medical research with no assurance that the resulting innovations would be available to our people should a future health crisis arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its push of one-on-one deals were upending frameworks previously established through the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This mechanism is designed to guarantee that when a country contributes its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our US partners on how future co-operation could be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
Medical experts expressed it recognised the official position, but suggested that talks must proceed considering much of the nation's HIV programmes depended on foreign aid.
"Where technical issues arise, including those relating to information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
The situation underscores the ongoing debate between receiving much-needed foreign assistance and protecting a country's data in an ever more interconnected world.